Funder: National Institutes of Health
Due Dates: February 21, 2025 (New/Renewal/Resubmission) | June 20, 2025 (New/Renewal/Resubmission)
Funding Amounts: No budget cap; budgets must reflect actual project needs. UG3 phase: 1–3 years; UH3 phase: up to 3 years; total project period not to exceed 5 years.
Summary: Supports development and cross-species evaluation of neurophysiological assays to bridge translational gaps in mental health treatment development.
Key Information: UG3/UH3 phased cooperative agreement; clinical trial optional; milestone-driven; strong data sharing and cross-species rigor required.